This paper shows how research by Quintiles indicates that study indicates that few subjects experiencing one symptom of neurocognitive decline ever visit their physician, suggesting that there is a large available pool of community-based patients who could potentially participate in pAD clinical trials. Subjects are willing to complete online assessments regarding their symptoms, and thus a digitally-based community outreach pre-screening campaign would help identify and screen potentially appropriate trial subjects, and eliminate inappropriate ones. Thus digital outreach can help make a significant reduction in the burden of work at the site by managing the pre-screening in the community and not within the site and then only a much smaller percentage of subjects would be brought, physically, to the site and the likely screen failure rates would decrease from the current 80% to the “usual” (for AD trials) at around 30 – 40%. Recruitment to pAD trials will depend on communication of positive messaging – via advertisements and within the patient informed consent – about the required trial assessments and their potential benefits to subjects and future AD sufferers.
White Paper April 28, 2014